Table 2.

Clinical characteristics of dystonia patients

Pt no.	Age	Sex	Side	Dystonia type	Disease duration, years	Medication, mg	TWSTRS/BFMDRS	Lead location, mm^{^a}			Movement task	Motor ECoG
Pt no.	Age	Sex	Side	Dystonia type	Disease duration, years	Medication, mg	TWSTRS/BFMDRS	Lat	AP	Vert	Movement task	Motor ECoG
1	61	M	R	Cervical	6	Baclofen 60, diazepam 20, trihexyphenidyl 6	33.75/6	19.5	3.5	−1.1	N	N
2	59	F	R	Craniocervical	10	Cyclobenzaprine 10	na/11	21.2	4.0	−0.7	N	Y
3	46	M	R	Craniocervical	23	Clonazepam 1	18/20	21.4	4.7	−1.6	N	Y
4	46	F	R	Craniocervical	14	Clonazepam 2	28/9	18.7	4.5	−1.1	Y	Y
5	56	F	R	Craniocervical	2	Cetirizine 10	20/7	18.6	3.5	−0.4	Y	Y
6	47	M	R	Cervical	5	Lorazepam 6	23/12	22.2	4.5	−2.6	Y	Y
7	34	M	R	Cervical	4	Clonazepam 1, baclofen 20	25/8	18.2	4.4	−2.0	Y	Y
8	47	F	L	DYT1+	37	Trihexyphenidyl 4	0/24	−19.3	7.5	−1.6	Y	Y
9	53	F	L	Generalized	11	Clonazepam 1^{^b}	12/51.5	−19.6	5.3	−1.2	Y	Y
10	37	M	R	DYT1+	29	Clonazepam 1	0/23	21.6	6.8	−0.2	Y	Y
11	57	F	R	Generalized	40	Clonazepam 1.5, diazepam 40	25/26	19.7	2.4	−1.9	Y	Y
12	26	M	L	Generalized	7	LEED 450², trihexyphenidyl 6	13/29	−20.3	6.3	−2.7	Y	Y
13	22	M	L	DYT1+	14	Baclofen 50, trihexyphenidyl 15	na/30.5	−23.1	1.5	−4.2	Y	N
14	35	M	R	Generalized	1	Baclofen 30, LED 600; cyclobenzaprine 15	18/11	21.2	4.7	−2.1	N	Y

↵^aLocation of the recording contact in anterior commissure and post-commissure plane.
↵^bMedication for Patient 9 was held 2 d prior to surgery.
DYT medication, Medications for dystonia; TWSTERS, Toronto Western Spasmodic Torticollis Rating Scale (motor severity score); BFMDRS, Burke–Fahn–Marsden Dystonia Rating Scale (movement subscale); Lat, lateral distance from mid-commissural point; AP, anterior–posterior distance from mid-commissural point; Vert, vertical distance from mid-commissural point; na, not available.